Phase II trials in second-line therapy for ovarian carcinoma show an overall 36% remission rate in 41 patients previously treated with cisplatin. Results were reported by Tate Thigpen, MD, University of Missipppi Medical Center at a recent meeting of the American Society of Clinical Oncologists. Of the 15 remissions, five were complete. Eight of the remissions, two complete and six partial, occurred in the 27 patients who were resistant to cisplatin therapy. The major adverse effect was myelosuppression which occurred in 65% of the women on taxol. Availability of the drug is limited since it must be extracted from tree bark.
You may also be interested in...
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
India is allowing importers and manufacturers of certain devices – for whom new licensing requirements came into effect on 1 January – to continue marketing their products for six months if they have already applied for a license. See what Rajiv Nath from the Association of Indian Medical Device Industry (AiMeD) said about it here.